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Background: To investigate the third-year results of ranibizumab monotherapy for polypoidal choroidal vasculopathy
(PCV) in individualized treatment regimens based on the outcomes during 2 years.
Methods: One hundred seventy-two consecutive eyes of 163 prospective treatment-naïve patients with PCV were treated
with three monthly intravitreal ranibizumab injections followed by as-needed reinjections and completed a 2-year
follow-up. Treatment regimens during the third year were selected individually based on their outcomes from the
following treatment regimens: as-needed injections based on quarterly examinations, as-needed injections based
on monthly examinations, a monthly ranibizumab injection schedule, and the treat-and-extend schedule. Visual acuity
(VA) and foveal thickness at the end of the third year and the prevalence of discontinuous follow-up examinations during
the third year were evaluated.
Results: Of 163 patients, 35 (21%) patients were excluded; nine patients had discontinuous follow-up examinations during
the third year. In 128 eyes of 128 patients studied during the third year, the significant improvements in VA and foveal
thickness 2 years after the first injection compared to baseline were maintained at the end of the third year. Six (18%,
6/34) patients treated with as-needed injections based on quarterly examinations had discontinuous follow-up
examinations, the prevalence of which differed significantly (P = 0.025) from the other groups.
Conclusions: The individualized treatment strategies in the third year based on each patient’s outcomes during 2 years
maintained the improved VA and avoided discontinuation of follow-up during the third year.
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The Seven-Year Observational Update of Macular De-
generation Patients Post-MARINA [1] (the Minimally
Classic/Occult Trial of the Anti-VEGF [vascular endo-
thelial growth factor] Antibody Ranibizumab in the
Treatment of Neovascular Age-Related Macular Degen-
eration [AMD])/ANCHOR [2] (the Treatment of Pre-
dominantly Classic Choroidal Neovascularization in
Age-related Macular Degeneration) and HORIZON [3]
(the Open-Label Extension Trial of Ranibizumab for
Choroidal Neovascularization Secondary to Age-Related
Macular Degeneration) trials [4] was conducted to assess
the long-term visual acuity (VA) outcomes and disease
status 7 to 8 years after initiation of intensive ranibizumabCorrespondence: taiichi-hikichi@hokkaido.med.or.jp
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apy and evaluate the risk of late visual decline over years 4
to 8 since leaving the HORIZON study [3]. At a mean
7.3 years after initiation of intensive ranibizumab treatment,
about one third of patients had a VA of 20/70 or better
Snellen equivalent, and almost one quarter had good vision
(20/40 or better). However, a third had poor vision (20/200
or worse). In half of patients, the fellow non-study eyes also
had wet AMD, and 6% of patients were legally blind, with
20/200 vision or worse bilaterally. The results suggested
that to maintain the VA gain in patients with neovascular
AMD treated with ranibizumab, patients may have to be
followed more frequently than quarterly or treated
more frequently. Recent trials [3-7] have reported that
as-needed ranibizumab injections based on monthly ex-
aminations could be effective if patients strictly adhereds an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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requires intensive long-term follow-up.
A previous study reported that monthly intravitreal
injections of ranibizumab for 3 months followed by an
as-needed reinjection schedule resulted in continued VA
improvement that was maintained throughout 2 years of
follow-up in eyes with polypoidal choroidal vasculopathy
(PCV) [8]. Although the mean ± standard deviation (SD)
total number of injections during 2 years was 5.6 ± 1.9
and the patients visited our clinic monthly according to
an as-needed reinjection schedule based on monthly ex-
aminations, the numbers of reinjections and the changes
in VA varied among patients. Because PCV is a chronic
disease and patients must be followed over the long term
[9,10], a strict treatment regimen is essential to maintain
favorable VA outcomes with ranibizumab therapy and
quality of vision and life [11-13]. However, it is difficult
to continue strict treatment regimens over the long
term. The treatment burden of aggressive as-needed
injections includes the injections themselves, monthly
visits (required for the optimal efficacy of as-needed
injection regimens), ancillary examinations to evaluate
the retreatment efficacy, and interpretation of the results
based on the retreatment criteria. Further, since the
degree of patient satisfaction with the results of ranibi-
zumab treatment and the status of the fellow eye vary,
adherence to and motivation to continue ranibizumab
treatment likely also vary among patients. The risk of a
marked decrease in VA has been reported during dis-
continuation of follow-up examinations, indicating that
regular examinations are warranted and that the major
reasons for discontinuation were sustained low VA and
lack of apparent treatment response [14].
Thus, at the end of the second year of an as-needed
reinjection schedule based on monthly examinations, to
avoid losing patients to follow-up, continue treatment,
and maintain the VA gains achieved during the 2-year
treatment, the treatment schedule for the third year was
changed from an as-needed reinjection schedule based
on monthly examinations of all patients to treatment
schedules based on the clinical course during the 2-year
follow-up period in each patient. The current study
reports the results after 3 years of ranibizumab therapy,
i.e., three monthly injections followed by as-needed rein-
jections based on monthly examinations for 2 years and
an individualized treatment regimen for the third year
based on the clinical course during the 2-year follow-up
period.Methods
One hundred seventy-two consecutive eyes of 163 pro-
spective treatment-naïve Japanese patients with symptom-
atic PCV who received monthly intravitreal injections of0.5 mg of ranibizumab for 3 months followed by a reinjec-
tion schedule based on need were followed for 2 years.
PCV was defined as the presence of one or multiple
focal areas of hyperfluorescence arising from the chor-
oidal circulation within the first 6 minutes after injection
of indocyanine green with or without an associated
branching vascular network. Polypoidal lesions are soli-
tary (arbitrarily defined as one or two polyps) or mul-
tiple, i.e., arranged in a ring or cluster [15-17]. There
were no exclusion criteria regarding the baseline VA or
lesion size. Most eyes in the current study were in our
previous study [8] that reported the 2-year outcomes of
ranibizumab monotherapy for PCV. Reinjections were
administered during the third year if any of the following
occurred [7,8]: visual loss determined using a decimal
VA chart, with fluid at the macula seen on optical coher-
ence tomography (OCT) images; any qualitative changes
seen on the OCT images that suggested recurrent fluid
in the macula including enlargement of a pigment
epithelial detachment; new macular hemorrhages; or
persistent fluid in the OCT images 1 month after the
previous injection. All criteria were based on compari-
sons with the previous examination. Since an as-needed
injection protocol was much tighter than that used pre-
viously and is often referred to as “zero tolerance”, [18]
any fluid seen on OCT images was added to the usual
retreatment criteria. When a reinjection was required,
intravitreal ranibizumab was administered on the same
day as the examination.
At the end of the second year of ranibizumab ther-
apy, one of the following four treatment schedules was
adopted during the third year for each patient after
they provided informed consent: 1) as-needed injections
based on quarterly examinations were administered if two
or fewer reinjections had been administered during the
second year, the treated eye was the nondominant eye
with 0.1 decimal VA (equivalent to 20/200 Snellen VA)
or worse, and the VA of the dominant fellow eye was
0.7 decimal VA (equivalent to about 20/30 Snellen VA)
or better; 2) as-needed injections based on monthly
examinations were continued even if two or fewer rein-
jections had been administered during the second year
and the patients did not meet the previous criterion; 3)
if five or more reinjections had been administered dur-
ing the second year, a monthly ranibizumab injection
schedule was adopted that included the dominant eye
or the eye with a VA decrease of 0.3 logarithm of the
minimum angle of resolution (logMAR) unit converted
from the decimal VA or more from the baseline log-
MAR VA during the 2-year follow-up period of as-
needed treatment based on monthly examinations; and
4) the treat-and-extend schedule [19] was adopted if
three or four reinjections had been administered dur-
ing the second year or the patients did not meet the
Table 1 The mean (± standard deviation) age and
number of ranibizumab injections in each treatment
schedule group
Treatment schedule No. injections





















(n = 61) 71 (8) 4.0 (1.2) 1.5 (0.9) 1.8 (1.1)
Monthly injection
schedule (n = 18)
75 (8) 4.3 (1.8) 5.5 (0.8) 11.4 (0.7)
Treat-and-extend
schedule (n = 21)
78 (7) 4.6 (1.0) 3.8 (0.6) 6.4 (2.4)
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been administered during the second year.
The institutional review board of Ohtsuka Eye Hospital
approved the treatment strategy. The current research
followed the tenets of the Declaration of Helsinki. All
patients provided informed consent after explanation of
the study protocol. Since aflibercept (Eylea, Regeneron,
Tarrytown, NY, and Bayer, Berlin, Germany) and bevacizu-
mab (Avastin, Genentech, Inc.) had not yet been approved
at the end of the second year of this study in Japan,
switching the anti-VEGF agents could not be considered
as a treatment strategy for neovascular AMD.
In cases with bilateral disease, the eye treated first
with ranibizumab was included in the current study.
The VA was measured with the Landolt ring chart.
Digital simultaneous fluorescein angiography and in-
docyanine green angiography images were obtained by
scanning laser ophthalmoscopy (Heidelberg Retina
Angiograph II, Heidelberg Engineering Inc., Dossenheim,
Germany) throughout the study. The foveal thickness
was based on the average foveal thickness on the verti-
cal and horizontal scans of OCT (OCT 3000, Zeiss
Humphrey Instruments, Dublin, CA or Spectralis,
Heidelberg Engineering Inc.). The VA was measured
and OCT was performed at every visit during the 3-year
follow-up period.
The logMAR unit calculated from the decimal VA was
used to analyze the VA. Statistical analysis was per-
formed using SPSS 11.5.1 for Windows software package
(SPSS Inc., Chicago, IL). Multiple comparisons were
performed by one-way analysis of variance with the
Scheffe’s F test. P < 0.05 was considered significant.
Results
Of 163 prospective treatment-naïve Japanese patients
who received ranibizumab therapy for 2 years, 18 pa-
tients chose to return to the clinics that referred them to
our institute for treatment of PCV at the end of the 2-year
treatment period. Eight patients were excluded from the
current study, because even though the patients met the
criteria of the monthly treatment schedule, they could not
return for monthly visits during the third year because of
proximity to the clinic, absence of available ophthalmic
clinicians, or the treatment schedule for as-needed injec-
tions based on quarterly examinations was selected for the
third-year treatment. Nine patients had discontinuous
follow-up examinations during the third year. Thus, 128
(79%, 128/163) eyes of 128 patients (mean ± SD age, 73 ±
8 years; range, 47–89 years) were studied in the analysis of
the clinical outcomes during the third year.
During the third year, 28 eyes received as-needed injec-
tions based on quarterly examinations, 61 eyes received as-
needed injections based on monthly examinations, 18 eyes
received monthly ranibizumab injections, and 21 eyes had atreat-and-extend schedule. Table 1 shows the mean age and
the number of ranibizumab injections in each treatment
group. Since the study eyes were divided into four groups
depending on the number of injections during the second
year, the numbers of injections during the second and third
years differed significantly (P = 0.01) between every two
groups.
Table 2 shows the mean (± SD) logMAR VA at various
times after the first injection. In 128 eyes, the VAs at 1, 2,
and 3 years after the first injection significantly (P = 0.01,
P = 0.01, and P = 0.04, respectively) improved compared to
the baseline VA. Although the VA decreased significantly
(P = 0.01) during the second year, the VA at the end of the
second year was maintained at the end of the third year
(Figure 1). In eyes treated with as-needed injections based
on quarterly examinations during the third year, the base-
line VA was the worst among the four groups, but the
baseline VA was maintained at the end of the third year.
However, the VA 3 years after the first injection decreased
significantly (P = 0.01) compared to the VA 2 years after
the first injection. In eyes treated with as-needed injec-
tions based on monthly examinations during the third
year, the VAs at 1, 2, and 3 years after the first injection
improved significantly (P = 0.01, for all comparisons) com-
pared with the baseline VA. Although the VA decreased
significantly (P = 0.01) during the second year, no differ-
ence was found in the VA between 2 and 3 years after the
first injection. In eyes receiving monthly injections, the
baseline VA was relatively good, but the VA 1 year after the
first injection improved significantly (P = 0.03) compared
Table 2 The mean (± standard deviation) visual acuity of the logarithm of the minimum angle of resolution at various
points after the first injection in each treatment schedule group
Treatment schedule
During the third year Baseline 1 year 2 years 3 years
All eyes (n = 128) 0.61 (0.51) 0.43 (0.43) 0.50 (0.42) 0.52 (0.47)
As-needed injections determined by quarterly examination schedule
(n = 28) 0.98 (0.58) 0.89 (0.46) 0.93 (0.45) 1.12 (0.49)
As-needed injections determined by monthly examination schedule
(n = 61) 0.48 (0.49) 0.23 (0.30) 0.30 (0.32) 0.30 (0.30)
Monthly injections schedule (n = 18) 0.34 (0.08) 0.21 (0.18) 0.38 (0.17) 0.35 (0.12)
Treat-and-extend schedule (n = 21) 0.72 (0.38) 0.55 (0.27) 0.63 (0.26) 0.52 (0.22)
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cantly (P = 0.01) during the second year, no difference was
found in the VA between years 2 and 3 after the first injec-
tion and the monthly injection maintained the VA during
the third year (Figure 1). In eyes on the treat-and-extend
schedule, the VA at 1 year after the first injection improved
significantly (P = 0.03) compared with the baseline VA.
The treat-and-extend treatment during the third year
significantly (P = 0.01) improved the VA compared to
the VA after the second year, which was significantly
decreased (P = 0.02) during the second year with as-
needed injections based on monthly examinations.
Table 3 shows the mean (± SD) foveal thicknesses at
various times after the primary injection. In the 128 eyes
and all four treatment groups during the third year, the
foveal thicknesses at 1, 2, and 3 years after the firstFigure 1 Improvement in the logarithm of the minimum angle of
resolution (logMAR) visual acuity (VA) at the end of the third year
in each treatment schedule. The white and shaded bars indicate
the changes from baseline and the 2-year values, respectively. The
positive values on the Y-axis indicate VA improvements at the end
of the third year compared to baseline or 2 years. PRN = pro re nata.
*P = 0.01; †P = 0.04; ‡P = 0.02.injection were significantly (P = 0.01, for all compari-
sons) thinner compared to baseline. No apparent differ-
ences were seen in the foveal thicknesses between years
2 and 3 in each treatment group, except that the mean
foveal thickness at 3 years was significantly thicker com-
pared to that at 2 years in the group treated with as-
needed injections based on quarterly examinations and
thinner compared to that at 2 years in the group treated
with monthly injections (P = 0.01 and P = 0.04, respectively)
(Figure 2).
At the beginning of the third year, 137 patients partici-
pated in this study, but nine patients discontinued
follow-up examinations during the third year. Thus, 93%
(128/137) of patients continued the third-year examina-
tions. Of the nine eyes, six (18%, 6/34) eyes were treated
with as-needed injections based on quarterly examina-
tions, two (3%, 2/63) eyes were treated with as-needed
injections based on monthly examinations, and one (5%,
1/22) eye was treated with the treat-and-extend sched-
ule. The numbers of the patients who had discontinuous
follow-up examinations differed significantly (P = 0.04)
among the groups.
No endophthalmitis, uveitis, lens damage, or pro-
longed intraocular pressure elevations occurred. Ten
eyes underwent cataract surgery during the third year.
In three eyes, the presence of minute amounts of
vitreous hemorrhage was thought to be associated
with the injection site at the uvea but spontaneously
resolved within a few days without medication.
Discussion
In this study, the treatment schedule during the third
year in each patient was based on the 2-year results with
as-needed injections, monthly examinations, and the VA
of the fellow eye. The improved VA in the 128 study
eyes at the end of the second year compared to the base-
line VA was maintained at the end of the third year.
Ninety-three percent of the patients who participated in
this study could have continued the follow-up examina-
tions during the third year.
Table 3 The mean (± standard deviation) foveal thickness (μm) at various points after the first injection in each
treatment schedule group
Treatment schedule
During the third year Baseline 1 year 2 years 3 years
All eyes (n = 128) 338 (127) 206 (69) 212 (62) 212 (55)
As-needed injections determined by quarterly examination schedule
(n = 28) 349 (154) 206 (60) 190 (39) 216 (41)
As-needed injections determined by monthly examination schedule
(n = 61) 303 (120) 201 (73) 200 (65) 198 (53)
Monthly injection schedule (n = 18) 380 (122) 214 (72) 255 (49) 231 (48)
Treat-and-extend schedule (n = 21) 377 (73) 213 (70) 239 (68) 225 (73)
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branching vascular network remains after anti-VEGF
therapy even when combined with photodynamic ther-
apy [8,11-13,20], which can result in recurrent poly-
poidal lesions, and clinical examinations are necessary
for the patients’ lifetimes. Because the fundus findings
and natural histories vary in eyes with PCV [9,10], the
numbers of required injections during the second year
also varied among eyes with PCV (Table 1). Further-
more, the VAs at the end of the second year varied
among the treated eyes and the VAs of the fellow eyes
probably differed in each patient. Retina specialists who
treat patients with AMD must maintain the patients’ ac-
tivities of daily living (ADL) while considering the treat-
ment outcomes and burden and medical expenses each
patient pays [21]. Thus, at the end of 2 years ofFigure 2 Changes in the foveal thickness at the end of the
third year in each treatment schedule. The white and shaded bars
indicate changes from the baseline and the 2-year values, respectively.
PRN= pro re nata. *P = 0.01; †P = 0.03.ranibizumab therapy, the treatment regimen in the third
year in eyes with PCV was changed from as-needed
injections based on monthly examinations to individual-
ized treatment strategies according to each patient’s
clinical course during the 2-year follow-up period.
In eyes treated with as-needed injections based on
monthly examinations, the monthly injection schedule,
and the treat-and-extend schedule in the third year, VAs
decreased significantly during the second year, but indi-
vidualized treatment strategies during the third year
could avoid the decreased VA. In eyes treated with the
treat-and-extend schedule, VA improved significantly
during the third year. On the contrary, in eyes treated
with as-needed injections based on quarterly examina-
tions, VA decreased significantly during the third year.
The outcomes of the four treatment strategies during
the third year in the current study showed that 1) as-
needed injections based on quarterly examinations re-
sulted in poor visual outcomes, 2) as-needed injections
based on monthly examinations maintained the vision of
good responders during the 2-year treatment with as-
needed injections based on monthly examinations, 3)
monthly injections maintained the vision of poor re-
sponders during the 2-year treatment with as-needed
injections based on monthly examinations, and 4) the
treat-and-extend schedule significantly improved the
vision of the moderate responders during the 2-year
treatment with as-needed injections based on monthly
examinations. Recent studies [3,5-7,22,23] have found
that strict treatment schedules are needed to obtain the
optimal effect of ranibizumab treatment over the long
term. Proactive treatment strategies such as monthly in-
jections and a treat-and-extend schedule, which require
frequent reinjections compared to as-needed injections
based on monthly examinations, may be considered in
eyes in which the outcomes of as-needed injections
based on monthly examinations were unfavorable.
The goal of this study was that patients continue to be
treated and follow the treatment schedule and that opti-
mal visual outcomes are maintained. Since only nine
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tions during the third year, the treatment strategy in this
study could avoid losing patients to follow-up and
continue treatment. Previously published data [24] from
the MARINA [2] and ANCHOR [1] trials showed that
the 25-item National Eye Institute Visual Function
Questionnaire scores improved whether patients were
treated in the better or worse eyes, but there was diffi-
culty reaching a clinically meaningful range [25-27] in
the worse-seeing eyes compared to the better-seeing
eyes. Maintaining treatment compliance and avoiding
interruptions in follow-up visits, consideration of the VA
of the fellow eye should be necessary to select the treat-
ment strategy. Furthermore, when dominant eyes are
treated and the fellow eyes have more severe visual loss,
even the temporary VA loss caused by the recurrent
exudative changes should affect the ability of patients to
perform their ADLs. Such patients want to avoid VA
fluctuations and may reject the as-needed injection
schedule. Thus, a monthly injection schedule was se-
lected for those patients in the current study.
At the start of the third year, the disadvantage asso-
ciated with quarterly examinations was anticipated and
this concern was shared with the patients and families.
When the treatment criteria with quarterly examinations
were considered, it was believed that even if the VA de-
creased during the third year, the disruption of the ADLs
would be minimal. The mean VA increased from base-
line to month 12 in the quarterly dosing groups in the
EXCITE study [28] by 4.0 letters of the Early Treatment
of Diabetic Retinopathy Study (ETDRS) chart in the
0.3 mg of ranibizumab quarterly group and 2.8 letters in
the 0.5-mg quarterly group, whereas in the PIER study
[29] that compared the efficacy of quarterly dosing of
ranibizumab with sham treatment, although superior to
sham treatment, the VA decreased over the 12-month
study period to −1.6 letters in the 0.3-mg quarterly and
−0.2 letter in the 0.5-mg quarterly groups. In the current
study, the baseline VA was not maintained in eyes
treated with as-needed injections based on quarterly
examinations. Those eyes responded poorly to as-needed
injections based on monthly examinations during 2 years.
In the current study, three (2%) of 128 eyes had mi-
nute amounts of vitreous hemorrhage after the injection
during the 3-year follow-up. Since no new hemorrhage
caused by PCV lesions was observed, the vitreous
hemorrhage was suggested to be associated with the
injection site in the uvea. In the 2-year results from the
MARINA [1] and ANCHOR [2] studies, the incidence of
vitreous hemorrhage was reported to be about 2%.
Since progression of retinal pigment epithelium (RPE)
atrophy is common in the natural history of PCV [9,10]
and photodynamic therapy (PDT) [30,31], progression of
RPE damage during the long-term follow-up period oftherapy in eyes with PCV may result in deteriorated visual
function. Thus, in the current study, PDT was not consid-
ered as a treatment strategy for PCV during the third year.
A limitation of the current study was that about 21%
of the eyes of prospective treatment-naïve Japanese
patients who received ranibizumab therapy for 2 years
could not participate in this study. This large number of
excluded patients may have introduced bias into the out-
comes, but this is a scenario in an ordinary clinic. An-
other limitation was that only ranibizumab was available
to treat neovascular AMD in Japan during the current
study. Recently, other anti-VEGF agents have been used
to treat neovascular AMD. Switching from ranibizumab
to another anti-VEGF agent may be an option for long-
term follow-up [32]. Furthermore, the results of each
treatment schedule during the third year were not sim-
ply compared, because the baseline VA levels and re-
sponses to ranibizumab during the 2-year treatment
differed among the groups. Thus, the results of this
study could not confirm which treatment schedule was
most effective.Conclusions
Despite the limitations, the potential to prevent VA
deterioration cannot be ignored, considering the current
encouraging long-term treatment outcomes. The im-
proved VA at the end of the second year compared to
baseline can be maintained for the third year in patients
with PCV treated with ranibizumab. PCV is a chronic
disorder and the current findings indicated that the need
for anti-VEGF treatment continues in patients with
PCV. Since discontinuation of the follow-up will result
in decreased VA, close follow-up should be warranted
[14]. However, since the degree of patient satisfaction
with the results of ranibizumab treatment and the status
of the fellow eye vary, adherence to and motivation to
continue ranibizumab treatment likely also vary among
patients, and a uniform treatment strategy seems to be
difficult to continue during long-term follow-up in all
patients. Thus, individualized treatment strategies based
on each patient’s situations should be necessary to not
interrupt follow-up. The current study indicated that in-
dividualized treatment strategies based on each patient’s
clinical course during 2 years maintained the improved
VA during the third year. Additional studies are war-
ranted to establish a reasonable treatment schedule for
patients with PCV who must be followed for the remain-
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